Human omentin-1 reduces vascular insulin resistance and hypertension in Otsuka Long-Evans Tokushima Fatty rats

Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3379-3387. doi: 10.1007/s00210-023-02795-w. Epub 2023 Nov 13.

Abstract

Purpose: Hypertension is one of the major risk factors for renal failure and cardiovascular diseases, and is caused by various abnormalities including the contractility of blood vessels. Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which mimic human type 2 diabetes, are frequently used to study obesity-induced insulin resistance (IR) and hypertension. Human omentin-1 is one of the recently identified adipocytokines. We previously demonstrated that human omentin-1 not only caused vasodilation in rat isolated blood vessels, but also prevented inflammatory responses, a possible mechanism relating IR, in human vascular endothelial cells. Taken together, we hypothesized that human omentin-1 may reduce obesity-induced IR and hypertension in OLETF rats.

Methods: OLETF rats were intraperitoneally administered with human omentin-1 for 7 days.

Results: Human omentin-1 had no influence on overweight, hyperglycemia, urinary glucose extraction, hyperinsulinemia, and systemic IR in OLETF rats. Human omentin-1 decreased systolic blood pressure in OLETF rats. The measurement of isometric contraction revealed that human omentin-1 had no influence on the agonist-induced contractile and relaxant responses in isolated thoracic aorta from OLETF rats. However, the relaxant response mediated by human insulin was converted into the contractile response in thoracic aorta from OLETF rats, which was prevented by human omentin-1. The Western blotting revealed that human omentin-1 improved the decrease in endothelial nitric oxide synthase activation in isolated thoracic aorta from OLETF rats.

Conclusion: In summary, we for the first time revealed that human omentin-1 partly reduces vascular IR and thereby inhibits hypertension in OLETF rats.

Keywords: Adipocytokine; Arterial contractility; Diabetes; Hypertension; Insulin resistance; Systolic blood pressure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Blood Pressure / drug effects
  • Cytokines* / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • GPI-Linked Proteins* / pharmacology
  • Humans
  • Hypertension* / drug therapy
  • Hypertension* / physiopathology
  • Insulin Resistance*
  • Lectins* / pharmacology
  • Male
  • Nitric Oxide Synthase Type III / metabolism
  • Obesity / metabolism
  • Obesity / physiopathology
  • Rats
  • Rats, Inbred OLETF*

Substances

  • Lectins
  • GPI-Linked Proteins
  • ITLN1 protein, human
  • Cytokines
  • Nitric Oxide Synthase Type III
  • Blood Glucose